CClinicalTrials.gg
Status unknownNCT04807725Updated Mar 23, 2022

Analysis of Genetic Variations in Patients With Peri-implantitis

An observational study in Peri-Implantitis, sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL. Status unknown at 1 site in Portugal. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL · Observational

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
88
Sex
All
01

Study summary

The primary objective of this study is to evaluate interleukin-1(IL-1) gene group polymorphisms in patients with peri-implantitis and to compare them with patients with peri-implant health (control group), taking into account smoking status, gender, age and history of periodontitis.The aim of this investigation is also to look at the levels of the inflammatory response markers IL-1 beta, prostaglandin E2 (PGE2) and tumor necrosis factor alpha (TNF alpha) in the peri-implant crevicular fluid of patients with healthy oral implants in comparison with individuals with peri-implantitis, under consideration of the patients´ individual IL-1 genotype.

The main hypothesis is that individuals carrying the polymorphism in the IL-1 gene cluster are susceptible to develop peri-implantitis through altered IL-1 and IL-1 receptor antagonist (IL-1Ra) production. A second hypothesis is that both in healthy individuals and especially pronounced in patients having peri-implantitis, an IL-1-positive genotype will result in higher levels of inflammatory cytokines (IL-1 beta, PGE2 and TNF alpha) than an IL-1- negative genotype.

Patients included in the study will be recruited from the Dental Clinic Egas Moniz implant maintenance program and will only be used for this study. All possible candidates will receive a questionnaire and if the patient's medical history is in accordance with study inclusion criteria, and if they agree to participate, informed consent will be signed. All clinical data will be collected by the same examiner.

Genes IL-1A and IL-1B control the production of the proinflammatory proteins, IL-1 alpha and IL-1 beta, respectively. IL-1RN gene controls the synthesis of the IL-1Ra, which impedes the function of IL-1alpha and IL-1beta by competing for receptor binding. Polymorphisms of the following genes will be analyzed: IL-1A-889, IL-1B + 3954, IL-1B-511 and IL-1 RN from patients with peri-implantitis and peri-implant health. For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab.

For the biochemical analysis of the inflammatory mediators IL-1 beta, TNF alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.

Read the detailed description

The study will be conducted according to the principles of the Helsinki Declaration (reviewed in 2013). Appropriate measures will be taken for the protection of patient data. The study was approved by Instituto Universitário Egas Moniz (IUEM) Scientific Council on 3 July 2019 and the approval of the Ethics Committee of Egas Moniz was received on 24 July 2019. Authorization was also obtained by the Clinical Direction of Egas Moniz Dental Clinic to carry out research work at the Clinic of the University.

The study will consist of two groups, the first consisting of patients with peri-implantitis (bleeding and / or suppuration on probing, probing depth (PD) equal or greater than 6mm and bone loss equal to or greater than 3mm) and the second group (control group) formed by patients with peri-implant health (peri implant mucosa without inflammatory signs and absence of peri-implant bone loss). The definition of peri-implantitis and peri-implant health will be in accordance with the new classification of periodontal and peri-implant diseases (American Academy of Periodontology (AAP) and European Federation of Periodontology (EFP) 2017)

A peri-implant probing examination (6 locations with a CP12 graduated periodontal probe) and evaluation of plaque accumulation and gingival indexes (4 locations) will be performed as usual at implant maintenance appointments. The presence of bleeding on probing or pus will also be evaluated. An implant control radiograph will be taken in cases where there is a probing depth more than 6mm. All clinical data will be collected by the same examiner. Prior to the study, a training and calibration exercise will be performed for PD measurements using patients not included in the study.

The periodontal condition of the patients will be also evaluated. To consider periodontal health, patients should have the following clinical characteristics: up to 10% of locations with bleeding on probing, absence of erythema and edema, absence of patient symptoms, absence of clinical attachment loss and bone loss and PD \< 3mm (AAP and EFP 2017). A patient is a periodontitis case if: interdental clinical attachment loss is detectable at least 2 non-adjacent teeth, or buccal or oral clinical attachment loss >3mm with pocketing >3mm is detectable at least 2 teeth. The classification of periodontitis will be done on a multi-dimensional staging and grading system.

In the case of a peri-implant health situation, plaque control measures will be taken, while in cases of peri-implantitis the patient will be referred for a specific treatment appointment. In situations of patients with more than one implant affected by peri-implantitis, the one with the greatest bone loss will be chosen for the study.

The genetic analysis will be done at the IUEM Molecular Biology Laboratory with the DNA extraction technique followed by polymerase chain reaction followed by restriction fragment length polymorphism.

For the biochemical analysis the paper strips will be inserted into the peri-implant sulcus/ pocket until resistance is felt, waiting 30 seconds before removal. Visually contaminated samples (blood) will be discarded. Subsequently paper strips will be placed on Periotron® 8000 (Periotron Ide-interstate, NY, USA) for quantification of the collected peri-implant crevicular fluid volume. The strips of paper will then be placed in eppendorf tubes with filter and frozen at -80ºC until shipment to the Universidad Complutense de Madrid. At this university, the concentration of inflammatory mediators IL-1 beta and TNF alpha will be analyzed using multiplexed fluorescent sphere immunoassays using the Luminex® 100/200™ system and PGE2 by enzyme-linked immunosorbent assay (ELISA).

The prevalence of IL-1 gene group polymorphisms in patients with peri-implantitis and healthy ones will be compared by using appropriate inferential statistics methodologies (bivariate analysis/association tests), taking into account several sociodemographic and clinical variables: smoking status, gender, age and history of periodontitis. Based on a medium effect size (w=0.3), with 80% power and a 5% alpha level, the sample size for this study was calculated as n=88, thus, n= 44 for each group (periimplantitis and peri-implant health). Further, a multivariable regression logistic model will be constructed in order to evaluate the effect of those covariables and quantify the risk, through determination of the correspondent adjusted Odds Ratio (OR), towards the presence of peri-implantitis. Additionally, the levels of the inflammatory response markers IL-1 beta, PGE2 and TNF-alpha, present in the peri-implant crevicular fluid, will be compared between the group of patients with peri-implantitis and the patients with healthy oral implants, taking into account the above mentioned variables, by using appropriate inferential statistics methodologies (parametric/non parametric tests). All inferential analysis will be performed at a 5% significance level.

02

Conditions studied

  • Peri-Implantitis

Browse trials for

Keywords

  • peri-implantitis
  • gene polymorphisms
  • interleukin-1
  • dental implants
03

In context

Peri-Implantitis

304 studies on the registry are indexed under Peri-Implantitis; 84 are open to participants now.

This study's planned enrollment of 88 is close to the median of 80 across 116 observational studies indexed under Peri-Implantitis.

Browse Peri-Implantitis studies →

Lead sponsor

Egas Moniz - Cooperativa de Ensino Superior, CRL is the lead sponsor of 40 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients included in the study will be recruited from the Dental Clinic Egas Moniz implant maintenance program and will only be used for this study. All possible candidates will receive a questionnaire and if the patient's medical history is in accordance with study inclusion criteria, and if they agree to participate, informed consent will be signed.

Inclusion criteria

  • patients with Caucasian parents and grandparents
  • patients with dental implants placed at the Dental Clinic Egas Moniz or out
  • patients with peri-implantitis diagnosis
  • implants in function for at least 1 year
  • patients included in a periodontal / peri-implant support program
  • patients who agree to participate in the study and sign informed consent

Exclusion criteria

Exclusion Criteria:

  • patients with any systemic condition that affects the immune system
  • pregnant women
  • patients who have taken chronic antibiotics or anti-inflammatory drugs in the last 6 months
  • patients who have undergone peri-implant treatment in the area to be evaluated
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
88 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Peri-implant health

    Includes patients with peri implant mucosa without inflammatory signs and absence of peri-implant bone loss.

    Genetic: Analysis of genetic polymorphisms · Other: Biochemical analysis

  • Peri-implantitis

    Includes patients with bleeding and / or suppuration on probing, probing depth equal or greater than 6mm and bone loss equal to or greater than 3mm.

    Genetic: Analysis of genetic polymorphisms · Other: Biochemical analysis

Interventions

  • GeneticAnalysis of genetic polymorphisms

    For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).

  • OtherBiochemical analysis

    For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.

06

What researchers measure

Primary outcomes

  1. Frequency of Participants with polymorphism in the IL-1 gene cluster

    In the IL-1A-889 gene, two possible alleles are expected to be found, allele 1 (83 base pairs (bp) + 16 bp), allele 2 - allele with nucleotide sequence changed (99 bp). In the IL-1B + 3954 gene, two possible alleles are expected to be found, allele 1 (12 bp + 85 bp + 97 bp), allele 2 (12 bp + 182 bp). In the IL-1B-511 gene, two possible alleles are expected to be found, allele 1 (190bp + 114bp), allele 2 (304 bp). In relation to the polymorphism of the IL-1RN gene, 5 possible alleles are expected to be found according to the repeated base pair sequences: allele 1 (410 bp), allele 2 (240 bp), allele 3 (500 bp), allele 4 (325 bp), allele 5 (595 bp).

    Time frame: 1 month after sample collection

Secondary outcomes

  1. Concentration of inflammatory response markers IL-1 beta, PGE2 and TNF-alpha

    The paper strips with peri-implant crevicular fluid (PICF) will be placed on Periotron® 8000 (Periotron Ide-interstate, NY, USA) for quantification of the collected PICF volume.The concentration of inflammatory mediators IL-1beta and TNF-alpha will be analyzed using multiplexed fluorescent sphere immunoassays using the Luminex® 100/200™ system and PGE2 by ELISA (enzyme-linked immunosorbent assay).

    Time frame: 1 month after sample collection

07

Study locations

1 of 1 sites recruiting
  • Instituto Universitário Egas Moniz
    Almada, Monte De Caparica 2829-511, Portugal
    Recruiting
08

References and documents

Publications

  • Chen X, Zhao Y. Genetic Involvement in Dental Implant Failure: Association With Polymorphisms of Genes Modulating Inflammatory Responses and Bone Metabolism. J Oral Implantol. 2019 Aug;45(4):318-326. doi: 10.1563/aaid-joi-D-18-00212. Epub 2019 Jun 17. PubMed 31207194 ↗
  • Duarte PM, de Mendonca AC, Maximo MB, Santos VR, Bastos MF, Nociti Junior FH. Differential cytokine expressions affect the severity of peri-implant disease. Clin Oral Implants Res. 2009 May;20(5):514-20. doi: 10.1111/j.1600-0501.2008.01680.x. Epub 2009 Mar 11. PubMed 19302394 ↗
  • Feloutzis A, Lang NP, Tonetti MS, Burgin W, Bragger U, Buser D, Duff GW, Kornman KS. IL-1 gene polymorphism and smoking as risk factors for peri-implant bone loss in a well-maintained population. Clin Oral Implants Res. 2003 Feb;14(1):10-7. doi: 10.1034/j.1600-0501.2003.140102.x. PubMed 12562360 ↗
  • Gruica B, Wang HY, Lang NP, Buser D. Impact of IL-1 genotype and smoking status on the prognosis of osseointegrated implants. Clin Oral Implants Res. 2004 Aug;15(4):393-400. doi: 10.1111/j.1600-0501.2004.01026.x. PubMed 15248873 ↗
  • Lachmann S, Kimmerle-Muller E, Axmann D, Scheideler L, Weber H, Haas R. Associations between peri-implant crevicular fluid volume, concentrations of crevicular inflammatory mediators, and composite IL-1A -889 and IL-1B +3954 genotype. A cross-sectional study on implant recall patients with and without clinical signs of peri-implantitis. Clin Oral Implants Res. 2007 Apr;18(2):212-23. doi: 10.1111/j.1600-0501.2006.01322.x. PubMed 17348886 ↗
  • Petkovic-Curcin A, Zeljic K, Cikota-Aleksic B, Dakovic D, Tatic Z, Magic Z. Association of Cytokine Gene Polymorphism with Peri-implantitis Risk. Int J Oral Maxillofac Implants. 2017 Sep/Oct;32(5):e241-e248. doi: 10.11607/jomi.5814. PubMed 28906511 ↗
  • He K, Jian F, He T, Tang H, Huang B, Wei N. Analysis of the association of TNF-alpha, IL-1A, and IL-1B polymorphisms with peri-implantitis in a Chinese non-smoking population. Clin Oral Investig. 2020 Feb;24(2):693-699. doi: 10.1007/s00784-019-02968-z. Epub 2019 May 24. PubMed 31127430 ↗
  • McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum. 1995 Feb;38(2):221-8. doi: 10.1002/art.1780380210. PubMed 7848312 ↗
  • Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993 May;91(4):403-4. doi: 10.1007/BF00217368. PubMed 8500797 ↗
  • Hamdy AA, Ebrahem MA. The effect of interleukin-1 allele 2 genotype (IL-1a(-889) and IL-1b(+3954)) on the individual's susceptibility to peri-implantitis: case-control study. J Oral Implantol. 2011 Jun;37(3):325-34. doi: 10.1563/AAID-JOI-D-09-00117.1. Epub 2010 Jun 16. PubMed 20594066 ↗
  • Dereka X, Mardas N, Chin S, Petrie A, Donos N. A systematic review on the association between genetic predisposition and dental implant biological complications. Clin Oral Implants Res. 2012 Jul;23(7):775-88. doi: 10.1111/j.1600-0501.2011.02329.x. Epub 2011 Dec 12. PubMed 22151432 ↗
  • Laine ML, Leonhardt A, Roos-Jansaker AM, Pena AS, van Winkelhoff AJ, Winkel EG, Renvert S. IL-1RN gene polymorphism is associated with peri-implantitis. Clin Oral Implants Res. 2006 Aug;17(4):380-5. doi: 10.1111/j.1600-0501.2006.01249.x. PubMed 16907768 ↗
  • Huynh-Ba G, Lang NP, Tonetti MS, Zwahlen M, Salvi GE. Association of the composite IL-1 genotype with peri-implantitis: a systematic review. Clin Oral Implants Res. 2008 Nov;19(11):1154-62. doi: 10.1111/j.1600-0501.2008.01596.x. PubMed 18983319 ↗
  • Andreiotelli M, Koutayas SO, Madianos PN, Strub JR. Relationship between interleukin-1 genotype and peri-implantitis: a literature review. Quintessence Int. 2008 Apr;39(4):289-98. PubMed 19081897 ↗
  • Liao J, Li C, Wang Y, Ten M, Sun X, Tian A, Zhang Q, Liang X. Meta-analysis of the association between common interleukin-1 polymorphisms and dental implant failure. Mol Biol Rep. 2014 May;41(5):2789-98. doi: 10.1007/s11033-014-3133-6. Epub 2014 Jan 23. PubMed 24452718 ↗
  • Fourmousis I, Vlachos M. Genetic Risk Factors for the Development of Periimplantitis. Implant Dent. 2019 Apr;28(2):103-114. doi: 10.1097/ID.0000000000000874. PubMed 30865053 ↗
  • Vaz P, Gallas MM, Braga AC, Sampaio-Fernandes JC, Felino A, Tavares P. IL1 gene polymorphisms and unsuccessful dental implants. Clin Oral Implants Res. 2012 Dec;23(12):1404-13. doi: 10.1111/j.1600-0501.2011.02322.x. Epub 2011 Nov 10. PubMed 22092925 ↗

Individual participant data

Plan to share: No — The collections of DNA samples were collected only for the purpose of analyzing the polymorphisms of the IL-1 gene group. Participants authorized their collection only for this purpose. For ethical and confidentiality reasons, these samples may not be accessible to other researchers. DNA samples will be eliminated after conducting the study.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04807725
Lead sponsor
Egas Moniz - Cooperativa de Ensino Superior, CRL
Collaborators
Oral Reconstruction Foudation
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Mar 9, 2021
Primary completion
Jul 29, 2022 (estimated)
Completion
Jul 29, 2022 (estimated)
Last update
Mar 23, 2022

Study contacts

Ricardo Alves, Phd
Contact
ralves@egasmoniz.edu.pt
00351212946767
Ricardo Alves, Phd
principal investigator · Egas Moniz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion